Asthma – Pipeline Review, H2 2019

Global Markets Direct’s, ‘Asthma – Pipeline Review, H2 2019’, provides an overview of the Asthma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Asthma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Asthma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Asthma

– The report reviews pipeline therapeutics for Asthma by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Asthma therapeutics and enlists all their major and minor projects

– The report assesses Asthma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Asthma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Asthma

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Asthma pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

2A Pharma AB

4D Pharma Plc

AB Science SA

AbbVie Inc

Abeome Corp

Adamis Pharmaceuticals Corp

Adare Pharmaceuticals Inc

Advagene Biopharma Co Ltd

Aerami Therapeutics

Akeso Biopharma Inc

Algomedix Inc

ALK-Abello AS

Allergan Plc

Amgen Inc

Amphastar Pharmaceuticals Inc

AnaptysBio Inc

AnGes Inc

Antisense Therapeutics Ltd

Apollo Endosurgery Inc

Apollo Therapeutics LLC

Aquilon Pharmaceuticals SA

Argenx SE

Artax Biopharma Inc

Artizan Biosciences Inc

ASIT Biotech SA

Aslan Pharmaceuticals Ltd

AstraZeneca Plc

Atrapos Therapeutics LLC

Aurigene Discovery Technologies Ltd

Avidin Ltd

Bai Shuo Beijing Pharmaceutical Technology Co Ltd

Biocon Ltd

BiOraliX BV

BiosanaPharma BV

Biotec Pharmacon ASA

Boehringer Ingelheim International GmbH

Celltrion Inc

Celon Pharma SA

Chiesi Farmaceutici SpA

Chronic Airway Therapeutics Ltd

ConMed Biosciences Inc

Crossject SA

CrystalGenomics Inc

CSL Ltd

CSPC Pharmaceutical Group Ltd

Cumberland Pharmaceuticals Inc

Cynata Therapeutics Ltd

Cytokinetics Inc

Daewoong Pharmaceutical Co Ltd

Daiichi Sankyo Co Ltd

Denceptor Therapeutics Ltd

Dnarx LLC

EffectorBio Inc

Eleusis Ltd

EmphyCorp Inc

Energenesis Biomedical Co Ltd

Enterprise Therapeutics Ltd

Enzychem Lifesciences Corp

ethris GmbH

EURRUS Biotech GmbH

Exotect LLC

F. Hoffmann-La Roche Ltd

Fibrotherapeutics Inc

Foresee Pharmaceuticals Co Ltd

Fountain Biopharma Inc

GeneFrontier Corp

Genentech Inc

Generium

GeneScience Pharmaceuticals Co Ltd

GlaxoSmithKline Plc

GlycoMira Therapeutics Inc

Gossamer Bio Inc

Harbour BioMed

HEC Pharm Co Ltd

Hovione FarmaCiencia SA

Humanigen Inc

iCeutica Inc

Icure Pharmaceutical Inc

IGE Therapeutics Inc

ILiAD Biotechnologies LLC

Immune Regulation Ltd

Inatherys

InKemia IUCT Group SA

Innovimmune Biotherapeutics Inc

Inspyr Therapeutics Inc

Intech Biopharm Ltd

Invion Ltd

Irex Pharma LLC

JHL Biotech Inc

JiangSu Qyuns Therapeutics Co Ltd

Kashiv BioSciences LLC

KBP BioSciences Co Ltd

Kissei Pharmaceutical Co Ltd

Kither Biotech Srl

KLUS Pharma Inc

Knopp Biosciences LLC

KoBioLabs Inc

Kyowa Kirin Co Ltd

Laboratorios LETI SL

Lead Discovery Center GmbH

LG Chem Ltd

Lignamed LLC

Longevity Biotech Inc

Mabtech Ltd

Mariposa Health Ltd

Medicenna Therapeutics Corp

Mercia Pharma Inc

Merck & Co Inc

Mitsubishi Tanabe Pharma Corp

Mycenax Biotech Inc

NAL Pharmaceuticals Ltd

NeoPharm Co Ltd

Neovacs SA

Novartis AG

OliX Pharmaceuticals Inc

Omeros Corp

OncoArendi Therapeutics SA

Oncostellae SL

Ono Pharmaceutical Co Ltd

OPKO Health Inc

Opsidio LLC

Orbis Biosciences Inc

Orchid Pharma Ltd

Oxagen Ltd

Palo BioFarma SL

Pantherics Inc

Paradigm Biopharmaceuticals Ltd

Paragen Bio Pty Ltd

Pfizer Inc

PharmAbcine Inc

PharmaKing Co Ltd

Pharmaxis Ltd

Pieris Pharmaceuticals Inc

Progenra Inc

Promedior Inc

Prommune Inc

Prous Institute for Biomedical Research SA

Pulmatrix Inc

Pulmokine Inc

Qu Biologics Inc

Qurient Co Ltd

RAFT Pharmaceuticals

RAPT Therapeutics Inc

Re-Pharm Ltd

Regeneron Pharmaceuticals Inc

Reliance Life Sciences Pvt Ltd

Respiratorius AB

Revalesio Corp

ReveraGen BioPharma Inc

Ribomic Inc

S-TARget therapeutics GmbH

Saje Pharma LLC

Sam-A Pharm Co Ltd

Seelos Therapeutics, Inc.

Shanghai Kexin Biotech Co Ltd

Shanghai Zhangjiang Biotech and Pharmaceutical Base Development Co Ltd

Shouyao Holding Co Ltd

SolAeroMed Inc

sterna biologicals Gmbh & Co KG

Sun Pharma Advanced Research Company Ltd

Suzhou Connect Biopharmaceuticals Ltd

Swecure AB

Synermore Biologics Co Ltd

Taiho Pharmaceutical Co Ltd

TaiwanJ Pharmaceuticals Co Ltd

TCF GmbH

Tetragenetics Inc

Teva Pharmaceutical Industries Ltd

TFF Pharmaceuticals Inc

The Geneva Biotech Center SA

Theravance Biopharma Inc

Torrent Pharmaceuticals Ltd

Translational Biosciences

Trio Medicines Ltd

Tunitas Therapeutics Inc

United BioPharma Inc

Vactech Oy

Vascular BioSciences

Vasomune Inc

Vectura Group Plc

Verona Pharma Plc

WhanIn Pharmaceutical Co Ltd

Xencor Inc

Yuhan Corp

Zai Lab Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 8

Asthma - Overview 9

Asthma - Therapeutics Development 10

Asthma - Therapeutics Assessment 38

Asthma - Companies Involved in Therapeutics Development 54

Asthma - Drug Profiles 112

Asthma - Dormant Projects 568

Asthma - Discontinued Products 594

Asthma - Product Development Milestones 600

Appendix 612

List of Tables

List of Tables

Number of Products under Development for Asthma, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..7), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..8), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..9), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Products under Development by Companies, H2 2019 (Contd..5), H2 2019

Products under Development by Companies, H2 2019 (Contd..6), H2 2019

Products under Development by Companies, H2 2019 (Contd..7), H2 2019

Products under Development by Companies, H2 2019 (Contd..8), H2 2019

Products under Development by Companies, H2 2019 (Contd..9), H2 2019

Products under Development by Companies, H2 2019 (Contd..10), H2 2019

Products under Development by Companies, H2 2019 (Contd..11), H2 2019

Products under Development by Companies, H2 2019 (Contd..12), H2 2019

Products under Development by Companies, H2 2019 (Contd..13), H2 2019

Products under Development by Companies, H2 2019 (Contd..14), H2 2019

Products under Development by Universities/Institutes, H2 2019

Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..4), H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..5), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..5), H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Asthma – Pipeline by 2A Pharma AB, H2 2019

Asthma – Pipeline by 4D Pharma Plc, H2 2019

List of Figures

List of Figures

Number of Products under Development for Asthma, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports